Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 7/20 | 0.70 |
| ▸ | ECE1 | P42892 | 5/20 | 0.68 |
| ▸ | IL1RN | P18510 | 5/20 | 0.66 |
| ▸ | ACE | P12821 | 2/20 | 0.64 |
| ▸ | ERAP1 | Q9NZ08 | 5/20 | 0.64 |
| ▸ | ANPEP | P15144 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29532162 | 1.00 | ERAP2 (0.70) | ERAP2ECE1IL1RNACEERAP1 | |
| SCHEMBL29531288 | 1.00 | ERAP2 (0.70) | ERAP2ECE1IL1RNACEERAP1 | |
| SCHEMBL30051984 | 0.96 | ERAP2 (0.67) | ERAP2ECE1IL1RNACEERAP1 | |
| SCHEMBL30051680 | 0.96 | ECE1 (0.66) | ERAP2ECE1IL1RNACEERAP1 | |
| SCHEMBL30051546 | 0.95 | ERAP2 (0.73) | ERAP2ECE1IL1RNACEERAP1 | |
| SCHEMBL29531545 | 0.95 | ERAP2 (0.73) | ERAP2ECE1IL1RNACEERAP1 | |
| SCHEMBL29531276 | 0.95 | ERAP2 (0.73) | ERAP2ECE1IL1RNACEERAP1 | |
| SCHEMBL29556559 | 0.94 | OPRM1 (0.62) | ERAP2ECE1IL1RNACEERAP1 | |
| SCHEMBL29555989 | 0.94 | OPRM1 (0.62) | ERAP2ECE1IL1RNACEERAP1 | |
| SCHEMBL30051690 | 0.93 | ERAP2 (0.73) | ERAP2ECE1IL1RNACEERAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| CN-119039382-B | Tripeptide with ACE (angiotensin converting enzyme) inhibitory activity of crocodile source as well as preparation method and application thereof | 中国科学院烟台海岸带研究所 | 2025-02-11 | — | — | CN | disclosed |
| CN-119039382-A | Tripeptide with ACE (angiotensin converting enzyme) inhibitory activity of crocodile source as well as preparation method and application thereof | 中国科学院烟台海岸带研究所 | 2024-11-29 | — | — | CN | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | ERAP2 831/4885ECE1 1629/4885IL1RN 1655/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | ERAP2 87/4885ECE1 997/4885IL1RN 966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.